Biohaven (BHVN) Competitors

BridgeBio Pharma (NASDAQ:BBIO) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.

Which has better valuation & earnings, BBIO or BHVN?

Biohaven has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$127.42M	48.97	-$535.76M	-$3.53	-9.31
Biohaven	N/A	N/A	-$408.17M	-$9.36	-1.68

Does the MarketBeat Community believe in BBIO or BHVN?

Biohaven received 231 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 72.47% of users gave BridgeBio Pharma an outperform vote while only 67.43% of users gave Biohaven an outperform vote.

Company	Underperform	Outperform
BridgeBio Pharma	Outperform Votes 179 72.47%	Underperform Votes 68 27.53%
Biohaven	Outperform Votes 410 67.43%	Underperform Votes 198 32.57%

Which has more risk and volatility, BBIO or BHVN?

BridgeBio Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Does the media favor BBIO or BHVN?

In the previous week, Biohaven had 8 more articles in the media than BridgeBio Pharma. MarketBeat recorded 25 mentions for Biohaven and 17 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.91 beat Biohaven's score of 0.80 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	9 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend BBIO or BHVN?

BridgeBio Pharma currently has a consensus target price of $57.09, suggesting a potential upside of 73.73%. Biohaven has a consensus target price of $59.46, suggesting a potential upside of 277.29%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
Biohaven	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.07

Is BBIO or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-241.44%	N/A	-75.69%
Biohaven	N/A	-225.12%	-158.89%

Do insiders & institutionals believe in BBIO or BHVN?

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 16.0% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biohaven beats BridgeBio Pharma on 10 of the 18 factors compared between the two stocks.